Cangrelor

Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP) -induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist[1][2].

Product Specifications

CAS Number

[163706-06-7]

Product Name Alternative

AR-C69931MX

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

P2Y Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/cangrelor.html

Solubility

10 mM in DMSO

Smiles

CSCCNC1=C2C(N([C@H]3[C@H](O)[C@H](O)[C@@H](COP(OP(C(Cl)(Cl)P(O)(O)=O)(O)=O)(O)=O)O3)C=N2)=NC(SCCC(F)(F)F)=N1

Molecular Formula

C17H25Cl2F3N5O12P3S2

Molecular Weight

776.36

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Bhattad VB, , et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019;7 (17) :408.|[2]Zhan T, Wei T, et al. Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice. Mol Immunol. 2020;120:83-92.|[3]Bekő K, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain. J Thromb Haemost. 2017;15 (6) :1223-1235.